

# Ion Channels and Epilepsy

HOLGER LERCHE, KARIN JURKAT-ROTT, AND FRANK LEHMANN-HORN\*

Ion channels provide the basis for the regulation of excitability in the central nervous system and in other excitable tissues such as skeletal and heart muscle. Consequently, mutations in ion channel encoding genes are found in a variety of inherited diseases associated with hyper- or hypoexcitability of the affected tissue, the so-called 'channelopathies.' An increasing number of epileptic syndromes belongs to this group of rare disorders: Autosomal dominant nocturnal frontal lobe epilepsy is caused by mutations in a neuronal nicotinic acetylcholine receptor (affected genes: *CHRNA4*, *CHRN2*), benign familial neonatal convulsions by mutations in potassium channels constituting the M-current (*KCNQ2*, *KCNQ3*), generalized epilepsy with febrile seizures plus by mutations in subunits of the voltage-gated sodium channel or the GABA<sub>A</sub> receptor (*SCN1B*, *SCN1A*, *GABRG2*), and episodic ataxia type 1—which is associated with epilepsy in a few patients—by mutations within another voltage-gated potassium channel (*KCNA1*). These rare disorders provide interesting models to study the etiology and pathophysiology of disturbed excitability in molecular detail. On the basis of genetic and electrophysiologic studies of the channelopathies, novel therapeutic strategies can be developed, as has been shown recently for the antiepileptic drug retigabine activating neuronal KCNQ potassium channels. © 2001 Wiley-Liss, Inc.

**KEY WORDS:** ion channel; epilepsy; genetics; electrophysiology; patch clamp

## INTRODUCTION

Epileptic seizures are induced by abnormal focal or generalized synchronized electrical discharges within the central nervous system (CNS). The equilibrium in communication between neurons is regulated by a network of excitatory and inhibitory circuits. Both enhancement of excitatory and impairment of inhibitory mechanisms will disturb this equilibrium, which may result in epileptic discharges. There are two basic mechanisms underlying the electrophysiological excitability of and the communication

between neurons: Axonal conduction is mediated by action potentials and signal transduction from cell to cell by synaptic transmission. Since ion channels provide the basis for these processes, any mutation-induced channel malfunction may directly alter brain excitability and can induce epileptic seizures.

Ion channels are membrane-spanning proteins forming selective pores for Na<sup>+</sup>, K<sup>+</sup>, Cl<sup>-</sup>, or Ca<sup>2+</sup> ions. During action potentials a precise control of ion channel gating is mediated by membrane voltage, during synaptic transmission by the binding of specific neurotrans-

mitters, such as acetylcholine (ACh). With regard to these basic principles, two distinct and structurally conserved classes of ion channels emerged during evolution, the voltage-gated and the ligand-gated channels [Hille, 1992].

---

*Ion channels are  
membrane-spanning  
proteins forming selective  
pores for Na<sup>+</sup>, K<sup>+</sup>,  
Cl<sup>-</sup>, or Ca<sup>2+</sup> ions.*

---

Since these two are the only channel types that so far have been shown to be affected by mutations causing epilepsy, other classes of ionic channels, e.g., those regulated by intracellular ions such as Ca<sup>2+</sup>, by nucleotides, or by cell volume, will not be considered in this article.

Over the last 10–15 years, the combination of electrophysiological and genetic studies has revealed an increasing number of inherited diseases associated with mutations in ion channel encoding genes. The first of these so-called ion channel disorders or 'channelopathies'

Holger Lerche is a neurophysiologist and clinical neurologist in the Departments of Applied Physiology and Neurology, University of Ulm, Germany. Main research interests are the genetics, pathophysiology, and therapy of inherited neurological diseases; in particular, inherited forms of epilepsy and the relationship to molecular mechanisms of ion channel gating.

Karin Jurkat-Rott is in the Department of Applied Physiology, University of Ulm, Germany. Research focus: Physiology and pathophysiology of cellular excitation and muscle excitation-contraction coupling; genetics and pathogenesis of hereditary muscle and channel diseases with respect to skeletal muscle and the central nervous system; data bases on diagnostic criteria.

Frank Lohmann-Horn is in the Department of Applied Physiology, University of Ulm, Germany. Research focus: Physio(patho)logy of cellular excitation, particularly structure–function relationships of ligand- and voltage-dependent ion channels, etiology and pathogenesis of hereditary ion channel diseases in neurology.

Grant sponsor: the Deutsche Forschungsgemeinschaft; Grant number: DFG Le1030/5-1; Grant sponsor: the Bundesministerium für Bildung und Forschung (BMBF) / Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Ulm, projects B1 and B8.

\*Correspondence to: Frank Lehmann-Horn, Department of Applied Physiology, University of Ulm, D-89069 Ulm, Germany. E-mail: frank.lehmann-horn@medizin.uni-ulm.de

DOI 10.1002/ajmg.1582

were found in skeletal muscle, the myotonias and periodic paralyses, caused by mutations in voltage-gated  $\text{Na}^+$ ,  $\text{Cl}^-$ , or  $\text{Ca}^{2+}$  channels. Subsequently, several disorders of the CNS, the episodic ataxias, familial hemiplegic migraine, spinocerebellar ataxia type 6, startle disease, and several epileptic syndromes, were identified as belonging to the growing family of channelopathies [Lehmann-Horn and Jurkat-Rott, 1999, 2000; Ptacek, 1999; Cannon, 2000]. The current review will focus on the pathophysiological mechanisms of the epileptic channelopathies in man. We will start with a short overview of the structure and function of voltage- and ligand-gated ion channels, then summarize the clinical, genetic, and pathophysiological concepts of the known epileptic channel syndromes and finally discuss the implications of the general contribution of mutated ion channels to the genetics and


therapy of the more common forms of epilepsy.

### STRUCTURE AND FUNCTION OF VOLTAGE-GATED CATION CHANNELS

Voltage-gated  $\text{K}^+$ ,  $\text{Na}^+$ , and  $\text{Ca}^{2+}$  channels consist of several subunits, a main  $\alpha$ -subunit constituting both the gating and permeation machinery of the channel and one or more smaller subunits with modifying functions, called  $\beta$ ,  $\gamma$ , or  $\delta$ . The  $\alpha$ -subunits have a common tetrameric structure of homologous domains (I–IV) each with six transmembrane segments (S1–S6). Whereas  $\text{K}^+$  channels are constituted by four identical domains, the about fourfold longer genes of  $\text{Na}^+$ - and  $\text{Ca}^{2+}$ -channel  $\alpha$ -subunits encode four homologous but distinct domains. In all voltage-gated cation channels, the S4 segments contain

four to eight positively charged residues conferring voltage dependence to the channel protein and the S5–S6 loops form the major part of the ionic pore with the selectivity filter (Figs. 3, 5, 7).

There are three main conformational states of voltage-gated channels, a closed, an open, and an inactivated state. At the resting potential the channels are in the closed and activatable state. Upon membrane depolarization, the voltage sensors move outward opening the 'activation gate' of the channel on a time-scale of milliseconds by a yet-unknown mechanism, and with sustained depolarization the channels inactivate spontaneously by closing of a different, 'inactivation' gate. Upon membrane repolarization, inactivated channels remain refractory to further openings for a certain period determined by the time needed for recovery from inactivation (Fig. 1). Typical modifying properties of the smaller  $\beta$ -,  $\gamma$ -, or



**Figure 1.** The three main conformational states of voltage-gated ion channels. From a closed state at the hyperpolarized resting membrane potential, channels open upon depolarization during an action potential via outward movement of the voltage sensors that open the activation gate. Some channels, such as the voltage-gated  $\text{Na}^+$  channel, inactivate spontaneously via closing of a different, inactivation gate, when depolarization is maintained. From the inactivated state they can only recover upon repolarization of the cell membrane before they are ready for another opening.

$\delta$ -subunits are the regulation of the amount of functional protein in the membrane or minor alterations of the kinetics or voltage dependence of channel gating [Lehmann-Horn and Jurkat-Rott, 1999; Catterall, 2000; Siegelbaum and Koester, 2000].

The time course of depolarization and repolarization during an action potential is conveyed by the gating of voltage-dependent  $\text{Na}^+$  and  $\text{K}^+$  channels: Activation of the  $\text{Na}^+$  inward current mediates the steep depolarizing phase, whereas fast inactivation of  $\text{Na}^+$  channels and activation of the outward  $\text{K}^+$  current are responsible for membrane repolarization. Consequently, disruption of fast  $\text{Na}^+$  channel inactivation or a decrease in  $\text{K}^+$  conductance leads to slowed or incomplete repolarization of the cell membrane, resulting in hyperexcitability and spontaneous series of action potentials. Both are the most common disease-causing mechanisms in the channelopathies. Main functions of


neuronal voltage-gated  $\text{Ca}^{2+}$  channels are the regulation of transmitter release in presynaptic nerve-terminals.

The different subunits, in particular the channel  $\alpha$ -subunits, are expressed tissue specifically. For example, there are several genes encoding different  $\text{Na}^+$  channel  $\alpha$ -subunits (*SCN1A-SCN11A*) that are expressed in skeletal muscle (*SCN4A*), heart muscle (*SCN5A*) or neuronal tissue; four of these subunits (*SCN1A*, *SCN2A*, *SCN3A*, and *SCN8A*) are considered to be responsible for the sodium current in brain [Goldin et al., 2000]. The tissue specificity explains why there are  $\text{Na}^+$  channel disorders with symptoms restricted to skeletal or heart muscle (myotonia or cardiac arrhythmia), or to the CNS (febrile and afebrile seizures). Whereas the relatively few different  $\text{Na}^+$  channels are structurally and functionally highly conserved among each other, a large variety of different voltage-gated  $\text{K}^+$  channel types with distinct electro-

physiological properties is known [Chandy and Gutman, 1995; Lehmann-Horn and Jurkat-Rott, 1999]. For example, there are inactivating (e.g., *KCNA1*) and noninactivating (e.g., *KCNQ1-5*)  $\text{K}^+$  channels and large differences in the kinetics of activation and inactivation have been described.

## STRUCTURE AND FUNCTION OF LIGAND-GATED ION CHANNELS

Ligand-gated channels are a group of ion channels activated by different neurotransmitters such as acetylcholine (ACh),  $\gamma$ -amino-butyric-acid (GABA), glycine, glutamate, or nucleotides. They are also composed of several subunits, usually four or five. In contrast to the voltage-gated cation channels, all subunits have a similar structure, with two to four transmembrane segments (M1–4, Fig. 2). They form a channel complex with each subunit contributing equally



to the ion conducting central pore formed by the M2 segments (Fig. 2). The pore is not as selective as in the voltage-gated channels and permeable either to cations, as in excitatory ACh or glutamate receptors, or to anions, such as in inhibitory GABA or glycine receptors.

---

***Ligand-gated channels are a group of ion channels activated by different neurotransmitters such as acetylcholine (ACh),  $\gamma$ -amino-butyric-acid (GABA), glycine, glutamate, or nucleotides.***

---

The binding sites for transmitters are located in long extracellular loops.

Similar to the voltage-gated channels, there are three main conformational states of the ligand-gated channels: closed, open, and desensitized. Binding of the transmitter opens the channel from the closed state and during constant presence of the transmitter desensitization will occur. Only after removal of the transmitter can the channel recover from desensitization and subsequently be available for another opening [Kandel and Siegelbaum, 2000].

Neuronal nicotinic ACh receptors (nAChR) have a pentameric structure of two  $\alpha$ - and three  $\beta$ -subunits (Fig. 2). Eight  $\alpha$ -( $\alpha_{2-9}$ ) and three  $\beta$ -( $\beta_{2-4}$ ) subunit isoforms are known to be expressed differentially in brain. Most abundantly found in all brain areas are the  $\alpha_4$ - and  $\beta_2$ -subunits encoded by the genes *CHRNA4* and *CHRN2*, which are both affected in autosomal dominant nocturnal frontal lobe epilepsy [Bertrand and Changeux, 1999]. GABA receptors belong to the same family of ligand-gated channels having the same pentameric structure. There are several different subunit classes of GABA<sub>A</sub> receptors ( $\alpha_{1-6}$ ,  $\beta_{1-3}$ ,  $\gamma_{1-3}$ ,  $\delta$ ,  $\epsilon$ ,  $\pi$ ,  $\rho_{1-3}$ ). The subunit composition most abundantly found in brain is probably

$2\alpha_12\beta_21\gamma_2$  [Mehta and Ticku, 1999; Sieghart et al., 1999].

**AUTOSOMAL DOMINANT NOCTURNAL FRONTAL LOBE EPILEPSY (ADNFLE)**

This disorder is characterized by frequent brief seizures with hyperkinetic or tonic manifestations occurring typically in clusters at night. Ictal video-electroencephalographic studies revealed partial seizures originating from the frontal lobe. The onset is usually in childhood, inheritance is autosomal dominant, and the penetrance approximately 70–80% [Scheffer et al., 1995; Picard et al., 2000]. ADNFLE has often been misdiagnosed as paroxysmal nocturnal dyskinesia, sleep disorders such as night terrors or nightmares, or hysteria [Scheffer et al., 1994]. In a large Australian family, linkage was found to chromosome 20q13.2 [Phillips et al., 1995] and subsequently a mutation was identified in the gene *CHRNA4* encoding the  $\alpha_4$ -subunit of a neuronal nicotinic acetylcholine receptor (nAChR), being the first ion channel mutation in an inherited form of epilepsy [Steinlein et al., 1995]. Two more mutations were found in *CHRNA4* [Steinlein et al., 1997a; Hirose et al., 1999; Phillips et al., 2000] and recently, two groups identified mutations in *CHRN2* [De Fusco et al., 2000; Phillips et al., 2001], the gene encoding the  $\beta_2$ -subunit of neuronal nAChR, located on chromosome 1. All mutations described so far reside in one of the M2 transmembrane segments lining the ion conducting pore of the ligand-gated channel (Fig. 2).

Functional expression of some of the known mutations in *Xenopus* oocytes or human embryonic kidney (HEK) cells revealed different effects on gating of heteromeric  $\alpha_4\beta_2$  channels. The first two studies of the S248F mutation postulated a decrease of the overall channel activity by enhanced desensitization, slowed recovery from desensitization, reduced single channel conductance, and reduced permeability for  $\text{Ca}^{2+}$  ions [Weiland et al., 1996; Kuryatov et al., 1997]. Further studies of

S248F and the 776ins3 mutations also revealed mechanisms that increase the activity of the channel. A use-dependent potentiation to repetitive ACh-expositions, absent in wild-type receptors, was found for both mutations, and the 776ins3 mutation revealed a 10-fold increase in ACh-sensitivity [Steinlein et al., 1997a; Bertrand et al., 1998; Figl et al., 1998]. On the other hand,  $\text{Ca}^{2+}$  permeability was reduced for both receptors [Bertrand et al., 1998]. First studies of the mutations in the  $\beta_2$ -subunit revealed only functional alterations that enhance channel activity. The V287L mutation showed a profound slowing of desensitization kinetics [De Fusco et al., 2000] and V287M showed a 10-fold increase in ACh-sensitivity [Phillips et al., 2001].  $\text{Ca}^{2+}$  permeability for V287L was normal. Thus, pathomechanisms that enhance the activity of the nAChR seem to predominate. A disease-causing hyperactivity of the channel is also supported by a study showing a threefold increase in sensitivity to block by carbamazepine of mutant nAChR, suggesting that the good therapeutic response of ADNFLE patients to this drug is at least in part due to carbamazepine block of the mutant channel [Picard et al., 1999].

---

***ADNFLE has often been misdiagnosed as paroxysmal nocturnal dyskinesia, sleep disorders such as night terrors or nightmares, or hysteria.***

---

How these changes in the electrophysiological properties of the nAChR induce frontal lobe seizures remains to be elucidated. Both the  $\alpha_4$ - and  $\beta_2$ -subunits are expressed abundantly in nearly all brain tissues without specificity to the frontal lobe or to projections into this region [Bertrand and Changeux, 1999]. Also, the nocturnal occurrence of the seizures is difficult to explain. Transgenic mice generated with either a knock-out or knock-in of the

$\alpha_4$ -subunit were not reported to develop seizures [Ross et al., 2000; Labarca et al., 2001].

### BENIGN FAMILIAL NEONATAL CONVULSIONS (BFNC)

BFNC is a rare dominantly inherited epileptic syndrome characterized by frequent brief seizures within the first days of life that typically disappear spontaneously after weeks to months. Neurological examination, interictal EEG, and development of these children are usually normal. The risk of recurring seizures later in life is about 15%. The penetrance is as high as 85% [Ronen et al., 1993; Plouin, 1994]. The disease was first mapped to the long arm of


chromosome 20 [Leppert et al., 1989] and a second locus on chromosome 8 has been described [Lewis et al., 1993].


***BFNC is a rare dominantly inherited epileptic syndrome characterized by frequent brief seizures within the first days of life that typically disappear spontaneously after weeks to months.***

Subsequently, mutations in two novel voltage-gated potassium channel genes, *KCNQ2* (20q13.3) [Biervert et al., 1998; Singh et al., 1998; Biervert and

Steinlein, 1999; Lerche et al., 1999; Miraglia del Giudice et al., 2000] and *KCNQ3* (8q24) [Charlier et al., 1998; Hirose et al., 2000], have been identified (Fig. 3).

The *KCNQ* gene family encodes delayed rectifier  $K^+$  channels that are mainly expressed in heart muscle (*KCNQ1*), in the CNS (*KCNQ2–5*), the inner ear (*KCNQ4*), and skeletal muscle (*KCNQ5*) [reviewed by Jentsch, 2000]. They are activated upon depolarization of the cell membrane and contribute to the repolarizing phase of the action potential. Mutations in four of the five genes identified cause inherited diseases. *KCNQ1* mutations cause cardiac arrhythmia in the long QT syndrome [Wang et al., 1996], *KCNQ2* and *KCNQ3* mutations cause epileptic seizures in BFNC (see above), and





*KCNQ4* mutations cause congenital deafness [Kubisch et al., 1999]. *KCNQ5* is the only channel in which disease-causing mutations have not been found thus far [Lerche et al., 2000a; Schröder et al., 2000]. Functional expression of the known mutations revealed a consistent reduction of the resulting potassium current in *KCNQ1–4* [Chouabe et al., 1997; Wollnik et al., 1997; Biervert et al., 1998; Schröder et al., 1998; Kubisch et al., 1999; Lerche et al., 1999] (Fig. 4). This leads to an impairment of membrane repolarization, explaining the occurrence of hyperexcitability in the affected tissues.


However, the effects on current reduction were quite different for channels expressed in heart muscle and outer hair cells compared to those expressed exclusively in brain. Whereas *KCNQ1* and *KCNQ4* mutations exhibited strong dominant negative effects on WT channels [Chouabe et al., 1997; Wollnik et al., 1997; Kubisch et al., 1999], *KCNQ2* and *KCNQ3* mutations did not. The latter cause a dominant disease by haploinsufficiency [Biervert et al., 1998; Schröder et al., 1998; Lerche et al., 1999]. Hence, the brain seems to be more sensitive to changes in  $\text{K}^+$  conductance inducing hyperexcitability

than heart muscle fibers, a fact that apparently applies similarly to the  $\text{Na}^+$  channel disorders in muscle and brain (see below).

After the discovery of the neuron-specific *KCNQ2* and *KCNQ3* channels, it was shown that both interact with each other, since the current size of *KCNQ2* is enhanced by about 10-fold upon coexpression with *KCNQ3*, which exhibits only very small currents when expressed alone [Yang et al., 1998]. Both channels most probably constitute the so-called ‘M-current,’ a neuronal  $\text{K}^+$  current known for several decades to play an important role in the regulation of the firing rate of neurons [Wang et al., 1998; Shapiro et al., 2000]. When the in vivo situation for dominant *KCNQ2* and *KCNQ3* mutations was mimicked in vitro by coexpressing, for example, WT and mutant *KCNQ2* with WT *KCNQ3* channels in a 1:1:2 ratio in *Xenopus* oocytes, the reduction in current size was only 20–25% compared to WT *KCNQ2* combined with *KCNQ3* [Schröder et al., 1998]. Thus, as stated above, relatively small changes of the M-current seem to be sufficient to cause epileptic seizures.

Disease-causing mutations in *KCNQ* channels are clustered in two

regions of the protein, in the P-loop between segments S5 and S6 constituting the pore region and in the long C-terminus, which is specific for this family of  $\text{K}^+$  channels (Fig. 3). The pore mutations should reduce  $\text{K}^+$  current by affecting ionic conductance, whereas the C-terminus is most probably responsible for assembly to heteromeric channels. Although the stoichiometry of *KCNQ* channels has not been examined so far, it is well known from other voltage-gated  $\text{K}^+$  channels that they assemble to form tetramers. A mutation in the C-terminal part of *KCNQ1* causing Jervell and Lange-Nielson syndrome disrupt assembly of *KCNQ1* channels [Schmitt et al., 2000] and experiments using chimeras between *KCNQ1*, *KCNQ2*, and *KCNQ3* channels show that the interaction of *KCNQ2* and *KCNQ3* channels is indeed mediated by this region [Lerche et al., 2000b; Maljevic et al., 2001]. Hence, C-terminal mutations probably reduce current size by inhibiting the formation of functional heteromers inserting into the cell membrane. This hypothesis corresponds well to a reduced surface expression of a *KCNQ2* mutant truncating the C-terminus. In contrast, pore mutations in *KCNQ2* and



*KCNQ3* did not affect surface expression [Schwake et al., 2000].

The question remains why the reduced *KCNQ2/KCNQ3* K<sup>+</sup> current results in seizures preferentially during the neonatal period. One possibility could be that the brain is generally more likely to develop seizures in this premature state than later in life [Swann et al., 1993]. Another explanation might be the differential expression of potassium channels during maturation, which may attribute a dominant role to *KCNQ* channels in central neurons within the first days to weeks of life. Either potassium channels of the *KCNQ* family could be upregulated during this period or other voltage-gated potassium channels could still not have reached their full expression level. Differential expression with reduced expression of *KCNQ3* during the first days of life [Tinel et al., 1998] and expression of a shorter splice variant of *KCNQ2* in fetal brain that

attenuates *KCNQ2* and *KCNQ3* channels upon coexpression [Smith et al., 2001] have been reported. However, it remains unclear how these findings contribute to the neonatal seizure phenotype.

### GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS (GEFS<sup>+</sup>) AND SEVERE MYOCLONIC EPILEPSY OF INFANCY (SMEI)

GEFS<sup>+</sup> was first described in 1997 and 1999 by the group of Scheffer, Berkovic and colleagues [Scheffer and Berkovic, 1997; Singh et al., 1999] as a childhood-onset syndrome featuring febrile convulsions and a variety of afebrile epileptic seizure types within the same pedigree with autosomal dominant inheritance. Most common was the febrile convulsion syndrome (FS), often with febrile seizures persisting after the sixth year of

life or in combination with afebrile generalized tonic-clonic seizures (called 'FS<sup>+</sup>'). The phenotypes FS and FS<sup>+</sup> were found in about two-thirds of affected individuals. According to the additional seizure types occurring in the remaining third of the patients, phenotypes such as 'FS<sup>+</sup> with absences,' 'FS<sup>+</sup> with myoclonic seizures,' or 'FS<sup>+</sup> with atonic seizures' were described. The most severe phenotype was myoclonic astatic epilepsy (MAE). Also, partial epilepsies occurred in rare cases ('FS<sup>+</sup> with temporal lobe epilepsy'). The penetrance was about 60%.


Severe myoclonic epilepsy of infancy as first described by Dravet [1978] is characterized by clonic and tonic-clonic seizures in the first year of life that are often prolonged and associated with fever. Later, patients have afebrile generalized seizures such as myoclonic, absence, or tonic-clonic, and also simple and complex partial seizures

occur. Developmental stagnation with dementia occurs in early childhood. In contrast to GEFS<sup>+</sup>, the syndrome is usually resistant to pharmacotherapy.

The first genetic defect in GEFS<sup>+</sup> was found by Wallace et al. [1998]. The authors described linkage to chromosome 19q13 and identified a point mutation within the gene *SCN1B* encoding the  $\beta_1$ -subunit of the voltage-gated Na<sup>+</sup> channel. The mutation predicts substitution of tryptophan for a cysteine residue at position 121 disrupting a disulfide bridge and changing the secondary structure of the  $\beta_1$ -subunit extracellular loop (Fig. 5). This leads to a loss of  $\beta$ -subunit function resulting electrophysiologically in a slight slowing of the inactivation time course of the resulting Na<sup>+</sup> current [Wallace et al., 1998]. Although the  $\beta_1$ -subunit is also expressed in skeletal muscle, interestingly, these patients were not reported to suffer from myotonia like others carrying mutations within the skeletal muscle Na<sup>+</sup> channel  $\alpha$ -subunit gene *SCN4A*. Hence, the brain seems to be more sensitive to such changes of excitability than skeletal muscle fibers, or, alternatively, there are different disease-causing mechanisms for both diseases, which is discussed in more detail below.

Subsequently, several groups found linkage to a cluster of genes encoding neuronal Na<sup>+</sup> channel  $\alpha$ -subunits on chromosome 2q21–33 and the first two point mutations were detected in *SCN1A* predicting amino acid changes within the voltage sensors (S4 segments) of domains II and IV [Escayg et al., 2000a] (Fig. 5). Recently, several more *SCN1A* mutations have been described [Escayg et al., 2001; Wallace et al., 2001a] (Fig. 5) and there is evidence for further genetic as well as clinical heterogeneity [Lerche et al., 2001].

Heterologous functional expression of the first two *SCN1A* mutations in segments II/S4 and IV/S4 using the highly conserved gene *SCN4A*, human embryonic kidney cells (tsA201), and the whole-cell patch clamp technique revealed only subtle changes in sodium channel fast inactivation and activation and no persistent current [Alekov et al.,



2000, 2001] (Fig. 6). The most obvious alteration of the IV/S4 mutant (R1460H) was a threefold acceleration of recovery from inactivation (Fig. 6B), which was also reported in a preliminary study with expression of the mutation in the *SCN1A* gene using *Xenopus* oocytes and two-microelectrode voltage clamping [Escayg et al., 2000b]. In addition, we found little acceleration of the activation time course at potentials more negative than  $-20$  mV for both mutations compared to wild-type channels (Fig. 6C). By shortening the refractory period after an action potential and the time of depolarization

needed to elicit an action potential, these alterations would increase membrane excitability.

However, the most obvious difference in gating for the II/S4 mutation (T685M) in comparison to the wild type was an enhancement of both fast and slow inactivation of the channel. The steady-state fast and slow inactivation curves were shifted by  $-10$  or  $-20$  mV, respectively, entry into slow inactivation was accelerated and recovery from slow inactivation significantly slowed. These alterations were also found for the IV/S4 mutation, although less pronounced (Fig. 6D,E) [Alekov et al., 2000, 2001].

Hence, the disease-causing mechanism of sodium channel mutations found in GEFS<sup>+</sup> might be a loss-of-function by enhanced inactivation of the channel.

---

***Hence, the disease-causing mechanism of sodium channel mutations found in GEFS<sup>+</sup> might be a loss-of-function by enhanced inactivation of the channel.***

---

The increase of excitability due to acceleration of recovery from fast inactivation or of the activation time course—which would have to exert its effect on excitatory neurons to explain the occurrence of epileptic seizures—may be too small, in particular for the II/S4 mutation. In contrast, enhancement of both fast and slow inactivation would decrease membrane excitability by reducing the number of available sodium channels. When acting on inhibitory neurons, this effect could be responsible for the occurrence of synchronous activity in neuronal circuits causing epileptic seizures.

These findings are in contrast to the gain-of-function mechanism by a failure of inactivation that has been shown for *SCN4A* mutations causing sodium channel disorders of skeletal muscle, like myotonia and periodic paralysis [Lehmann-Horn and Jurkat-Rott, 1999; Cannon, 2000; Mitrovic and Lerche, 2000]. Nonetheless, such a gain-of-function has also been shown to induce epileptic seizures in a transgenic mouse model in which an *SCN2A* mutation with slowing of the inactivation time course and increased persistent current was introduced. Only 25% of the animals survived beyond 6 months of age; death occurred due to severe status epilepticus [Kearney et al., 2001]. The gating defects of inactivation were much less pronounced than those found for *SCN4A* mutations causing myotonia, suggesting that the CNS reacts much more sensi-

tively to such alterations of excitability than muscle fibers, which seems to apply similarly for K<sup>+</sup> channel defects (see above).

Two recent advances in the genetics of idiopathic epilepsies support the hypothesis that a decrease of excitability of inhibitory neurons is the most important disease-causing mechanism for GEFS<sup>+</sup>-causing sodium channel mutations. First, only recently mutations in two GEFS<sup>+</sup> families were found in the  $\gamma_2$ -subunit of GABA<sub>A</sub> receptors. One of these families presented with a typical GEFS<sup>+</sup> phenotype (FS and FS<sup>+</sup>) [Baulac et al., 2001], the other with a frequent combination of FS and absence seizures besides other syndromes described in GEFS<sup>+</sup> [Wallace et al., 2001b]. The two mutations are located in different regions of the channel, one in the benzodiazepine binding domain in the N-terminal extracellular loop (R43Q) [Wallace et al., 2001b] and the other in the loop connecting transmembrane segments M2 and M3 (K289M) [Baulac et al., 2001]. Functional expression of the mutant receptor  $\gamma_2$ -subunits together with  $\alpha_1$ - and  $\beta_2$ -subunits revealed two distinct gating defects. Whereas mutation K289M reduced GABA-activated currents 10-fold, R43Q revealed normal GABA-activated currents, but abolished the sensitivity to benzodiazepines such that activation by diazepam was no longer present. Thus, both mutations lead to a loss-of-function of GABA<sub>A</sub> receptors, although for R43Q it has to be postulated that 'endozepines' do exist and can prevent the development of epileptic seizures in vivo [Wallace et al., 2001b]. For these mutations, undoubtedly a decrease of excitability in inhibitory neurons is the pathophysiological mechanism causing seizures, as it could similarly be explained by enhanced inactivation of sodium channels.

Second, novel mutations were identified in *SCN1A* causing a more severe phenotype than GEFS<sup>+</sup>, that is SMEI [Claes et al., 2001]. Most of these mutations predict an early stop codon and a truncated protein without function (Fig. 5), with regard to all we know about structure-function relationships of voltage-gated sodium channels [Cat-

terall, 2000]. Therefore, SMEI is a loss-of-function sodium channel disorder caused by haploinsufficiency and, from a genetic point of view, a severe allelic variant of GEFS<sup>+</sup>.

Finally, the loss of  $\beta_1$ -subunit function by the *SCN1B* mutation could also induce a loss-of-function of the sodium channel, since one of the major effects of the  $\beta_1$ -subunit upon coexpression with the  $\alpha$ -subunit is to increase the current amplitude [Catterall, 2000]. Altogether, loss-of-function mechanisms (in inhibitory neurons) seem to predominate and are common to all mutations causing GEFS<sup>+</sup> or SMEI.

### **EPISODIC ATAXIA TYPE 1 WITH MYOKYMIA (AND PARTIAL EPILEPSY)**

Another ion channel disorder with disturbed excitability of the CNS is episodic ataxia type 1 with myokymia (EA-1).

---

***Another ion channel disorder with disturbed excitability of the CNS is episodic ataxia type 1 with myokymia.***


---

Dysfunction occurs predominantly in the cerebellum. Patients suffer from brief kinesigenic attacks of gait and limb ataxia or cerebellar dysarthria. Intercitally they experience myokymia. In four families, partial epileptic seizures were also reported, occurring in some family members affected by ataxia or myokymia [van Dyke et al., 1975; Brunt and van Weerden, 1990; Zuberi et al., 1999; Eunson et al., 2000]. Zuberi et al. [1999] estimated a 10-fold increased risk to develop epilepsy when affected by EA-1.

Genetic analyses in EA-1 revealed linkage to chromosome 12p13 and mutations within the Shaker homologous gene *KCNA1* encoding the K<sup>+</sup> channel K<sub>v</sub>1.1 [Browne et al., 1994; Litt et al., 1994] (Fig. 7). Functional expression in *Xenopus* oocytes or mammalian cells resulted in a reduction of the K<sup>+</sup> currents either by diminished expression

# Voltage-gated K<sup>+</sup> channel

## Kv1.1



- episodic ataxia with myokymia (EA-1)
- partial epilepsy with EA-1 or myokymia
- ▲ isolated myokymia

**Figure 7.** Proposed transmembrane structure of the voltage-gated potassium channel Kv1.1, the human homolog of the Shaker K<sup>+</sup> channel, encoded by the gene *KCNA1*. Mutations cause episodic ataxia type 1 with myokymia, two mutations are associated with partial epilepsy, and one mutation causes isolated myokymia.

or shifts in voltage-dependence. According to these studies, both dominant negative effects on WT channels and haploinsufficiency can cause EA-1 [Adelman et al., 1995; Zerr et al., 1998; Bretschneider et al., 1999; Zuberi et al., 1999; Eunson et al., 2000]. A specific defect for those mutations going along with an epilepsy phenotype could not be found [Zuberi et al., 1999; Eunson et al., 2000]. In support of the hypothesis that *KCNA1* mutations can

induce epileptic seizures, a knock-out mouse model for Kv1.1 presented with an epileptic phenotype [Smart et al., 1998].

### ASSOCIATION OF ION CHANNEL DEFECTS WITH COMMON FORMS OF IDIOPATHIC EPILEPSY

Genetic linkage studies in a few large families with a presumably monogenic

trait of idiopathic generalized epilepsy (IGE) revealed loci on chromosomes 6p and 15q14 for juvenile myoclonic epilepsy [JME; 6p: Greenberg et al., 1988; Serratosa et al., 1996; Sander et al., 1997; 15q14: Elmslie et al., 1997] and on 8q24 for childhood absence epilepsy [CAE, Fong et al., 1998; Sugimoto et al., 2000]. In two linkage studies using a large number of smaller IGE families, the 8q24 locus was also found, while the 6p locus could not be verified [Zara et al., 1995]; other potential loci were described on 2q36, 3q26, and 14q23; 15q14 was confirmed [Sander et al., 2000]. Significant linkage to the JME locus on chromosome 15 was recently also described for Rolando epilepsy [Neubauer et al., 1998]. Until now, mutations in genes at these locations have not been identified but there are several ion channel or transporter encoding genes that are strong candidates: on chromosome 2q36 the chloride-bicarbonate exchanger gene *SLC4A3*, on 3q26 the voltage-gated K<sup>+</sup> channel  $\beta$ -subunit gene *KCNA1B* [Schultz et al., 1996], and the Cl<sup>-</sup> channel gene *CLCN2* [Cid et al., 1995], on 14q24 the Na<sup>+</sup>/Ca<sup>2+</sup>-exchanger gene *SLC8A2* [Li et al., 1994] and on 15q14 the  $\alpha_7$ -subunit gene of the neuronal nAChR *CHRNA7* [Chini et al., 1994].

Several ion channel encoding genes were tested in association studies and mutation screenings if they play a role in the genetics of IGE. For *KCNQ2* [Steinlein et al., 1999], *KCNQ3* [Haug et al., 2000a], *KCNJ3* and *KCNJ6* [Girk1 and Girk2: Hallmann et al., 2000], *KCNN3* [hKC3: Sander et al., 1999], *CACNA1A* [Sander et al., 1998], and *SCN1B* [Haug et al., 2000b], no association could be found. A possible association of a benign polymorphism in *CHRNA4* with IGE [Steinlein et al., 1997b] could not be confirmed in another study [Chioza et al., 2000].

Recently, a mutation was discovered in a patient with juvenile myoclonic epilepsy in the gene *CACNB4*, encoding the  $\beta_4$ -subunit of the high voltage-gated L-type Ca<sup>2+</sup> channel, and functional studies revealed differences in channel gating for this mutation com-

pared to the WT [Escayg et al., 2000c]. Naturally occurring mutations in different subunits of the same channel complex cause epilepsy with generalized spike and wave discharges in the EEG in several mouse models (Noebels, accompanying article). Mutations in *CACNA1A*, encoding the  $\alpha$ -subunit, cause episodic ataxia type II, familial hemiplegic migraine, or spinocerebellar ataxia type 6 in man [Ophoff et al., 1996; Zhuchenko et al., 1997]. Interestingly, the same mutation in *CACNB4* causing JME caused EA-2 in a Canadian family [Escayg et al., 2000c]. It remains to be proven in further studies if *CACNB4* is an 'epilepsy gene' involved in a larger number of IGE families.

## IMPLICATIONS FOR THERAPY

The discovery of genetic defects and, in particular, the electrophysiological characterization of mutant ion channels in hereditary forms of epilepsy elucidates pathophysiological concepts of hyperexcitability in the CNS. This knowledge enables new therapeutic strategies by antagonizing the epilepsy-causing mechanisms using the defective proteins as pharmacological targets. In the case of BFNC, a completely novel approach in the treatment of epilepsies emerged from identifying retigabine as an activator of M-currents conducted by *KCNQ2* and *KCNQ3*  $K^+$  channels. Retigabine shifts the voltage dependence of steady-state activation of these channels by about 20 mV in the negative direction so that they are active at the resting membrane potential. This stabilizes the cell membrane via hyperpolarization towards the  $K^+$  equilibrium potential [Rundtfeld and Netzer, 2000; Main et al., 2000a; Wickenden et al., 2000].

It has been shown that for openers of ATP-dependent  $K^+$  channels ( $K_{ATP}$  channels) that they reduce hyperexcitability and can reverse paralysis of biopsied skeletal muscle fibers from patients with myotonia or periodic paralysis in vitro by hyperpolarization of the cell membrane [Grafe et al., 1990; Quasthoff et al., 1990; Lerche et al., 1996]. Attempts to treat such patients

with  $K_{ATP}$  channel openers failed due to intolerable cardiovascular side effects, since  $K_{ATP}$  channels are expressed abundantly in heart, smooth muscle cells, and other tissues [Lawson, 2000]. In contrast, *KCNQ2* and *KCNQ3* channels are expressed specifically in neurons and, therefore, side effects of retigabine should be diminished, since it has no effect on *KCNQ1* channels expressed in the heart [Main et al., 2000b]. Clinical trials are currently under way.

## REFERENCES

- Adelman JP, Bond CT, Pessia M, Maylie J. 1995. Episodic ataxia results from voltage-dependent potassium channels with altered functions. *Neuron* 15:1449–1454.
- Alekov AK, Rahman MM, Mitrovic N, Lehmann-Horn F, Lerche H. 2000. A sodium channel mutation causing epilepsy in man exhibits subtle defects in fast inactivation and activation in vitro. *J Physiol* 529:533–539.
- Alekov AK, Rahman MM, Mitrovic N, Lehmann-Horn F, Lerche H. 2001. Enhanced inactivation and acceleration of activation of the sodium channel associated with epilepsy in man. *Eur J Neurosci* 13:2171–2176.
- Baulac S, Gourfinkel-An I, Picard F, Rosenberg-Bourgin M, Prud'homme J-F, Baulac M, Brice A, LeGuern E. 1999. A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33. *Am J Hum Genet* 65:1078–1085.
- Baulac S, Huberfeld G, Gourfinkel-An I, Mitropoulou G, Beranger A, Prud'homme JF, Baulac M, Brice A, Bruzzone R, LeGuern E. 2001. First genetic evidence of GABA-A receptor dysfunction in epilepsy: a mutation in the  $\gamma 2$ -subunit gene. *Nat Genet* 28:46–48.
- Bertrand D, Changeux JP. 1999. Nicotinic receptor: a prototype of allosteric ligand-gated ion channels and its possible implications in epilepsy. *Adv Neurol* 79:171–188.
- Bertrand S, Weiland S, Berkovic SF, Steinlein OK, Bertrand D. 1998. Properties of neuronal nicotinic acetylcholine receptor mutants from human suffering from autosomal dominant nocturnal frontal lobe epilepsy. *Br J Pharmacol* 125:751–760.
- Biervert C, Steinlein OK. 1999. Structural and mutational analysis of *KCNQ2*, the major gene locus for benign familial neonatal convulsions. *Hum Genet* 104:234–240.
- Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinlein OK. 1998. A potassium channel mutation in neonatal human epilepsy. *Science* 279:403–406.
- Bretschneider F, Wrisch A, Lehmann-Horn F, Grissmer S. 1999. Electrophysiological characterization of two mutant Kv1.1 potassium channels causing episodic ataxia type 1 in mammalian cells. *Eur J Neurosci* 11:2403–2412.
- Browne DL, Gancher ST, Nutt JG, Brunt ERP, Smith EA, Kramer P, Litt M. 1994. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, *KCN411*. *Nat Genet* 8:136–140.
- Brunt ER, van Weerden TW. 1990. Familial paroxysmal kinesigenic ataxia and continuous myokymia. *Brain* 113:1361–1382.
- Cannon SC. 2000. Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses. *Kidney Int* 57:772–779.
- Catterall WA. 2000. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. *Neuron* 26:13–25.
- Chandy KG, Gutman GA. 1995. Voltage-gated  $K^+$  channel genes. In: North RA, editor. *Handbook of receptors and channels. Ligand- and voltage-gated ion channels*. Boca Raton, FL: CRC Press. p 1–71.
- Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, Leppert M. 1998. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. *Nat Genet* 18:53–55.
- Chini B, Raimond E, Elgoyhen AB, Moralli D, Balzaretto M, Heinemann S. 1994. Molecular cloning and chromosomal localization of the human  $\alpha 7$ -nicotinic receptor subunit gene. *Genomics* 19:379–381.
- Chioza B, Goodwin H, Blower J, McCormick D, Nashef L, Asherson P, Makoff AJ. 2000. Failure to replicate association between the gene for the neuronal nicotinic acetylcholine receptor  $\alpha 4$  subunit (*CHRNA4*) and IGE. *Am J Med Genet* 96:814–816.
- Chouabe C, Neyroud N, Guicheney P, Lazdunski M, Romey G, Barhanin J. 1997. Properties of KvLQT1  $K^+$  channel mutations in Romano-Ward and Jervell and Lange-Nielsen inherited cardiac arrhythmias. *EMBO J* 16:5472–5479.
- Cid L, Montrose-Rafizadeh C, Smith DI, Guggino WB, Cutting GR. 1995. Cloning of a putative human voltage-gated chloride channel (CLC-2) cDNA widely expressed in human tissues. *Hum Mol Genet* 4:407–413.
- Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. 2001. De novo mutations in the sodium-channel gene *scn1a* cause severe myoclonic epilepsy of infancy. *Am J Hum Genet* 68:1327–1332.
- De Fusco M, Becchetti A, Patrignani A, Annesi G, Gambardella A, Quattrone A, Ballabio A, Wanke E, Casari G. 2000. The nicotinic receptor  $\beta 2$  subunit is mutant in nocturnal frontal lobe epilepsy. *Nat Genet* 26:275–276.
- Dravet C. 1978. Les épilepsies graves de l'enfant. *Vie Med* 8:543–548.
- Elmslie FV, Rees M, Williamson MP, Kerr M, Kjeldsen MJ, An Pang K, Sundqvist A, Friis ML, Chadwick D, Richens A, Covanis A, Santos M, Arzimanoglou A, Panayiotopoulos CP, Curtis D, Whitehouse WP, Gardiner RM. 1997. Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. *Hum Mol Genet* 6:1329–1334.
- Escayg AP, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, An-Gourfinkel I, Brice A, LeGuern E, Moulard B, Chaigne D, Buresi C, Malafosse A. 2000a. Mutations of

- SCN1A, encoding a neuronal sodium channel, in two families with GEFS<sup>+</sup>2. *Nat Genet* 24:343–345.
- Escayg AP, MacDonald BT, Spimpanato J, Goldin AL, Meisler MH. 2000b. Coding and noncoding variation in the neuronal sodium channel *SCN1A* in patients with epilepsy. *Soc Neurosci Abstr* 26:222.
- Escayg AP, De Waard M, Lee DD, Bichet D, Wolf P, Mayer T, Johnston J, Baloh R, Sander T, Meisler MH. 2000c. Coding and noncoding variation of the human calcium-channel  $\beta$ 4-subunit gene *CACNB4* in patients with idiopathic generalized epilepsy and episodic ataxia. *Am J Hum Genet* 66:1531–1539.
- Escayg A, Heils A, MacDonald BT, Haug K, Sander T, Meisler MH. 2001. A novel *SCN1A* mutation associated with generalized epilepsy with febrile seizures plus and prevalence of variants in patients with epilepsy. *Am J Hum Genet* 68:866–873.
- Eunson EL, Rea R, Zuberi SM, Youroukos S, Panayiotopoulos CP, Liguori R, Avoni P, McWilliam RC, Stephenson JBP, Hanna MG, Kullmann DM, Spauschus A. 2000. Clinical, genetic, and expression studies of mutations in the potassium channel gene *KCN41* reveal new phenotypic variability. *Ann Neurol* 48:647–656.
- Figl A, Viveshakul N, Shafaei N, Forsayeth J, Cohen BN. 1998. Two mutations linked to nocturnal frontal lobe epilepsy cause use-dependent potentiation of the nicotinic Ach response. *J Physiol* 513:655–670.
- Fong GCY, Shah PU, Gee MN, Serratos JM, Castroviejo IP, Khan S, Ravat SH, Mani J, Huang Y, Zhao HZ, Medina MT, Treiman LJ, Pineda G, Delgado-Escueta AV. 1998. Childhood absence epilepsy with tonic-clonic seizures and electroencephalogram 3–4-Hz spike and multispikes-slow wave complexes: linkage to chromosome 8q24. *Am J Hum Genet* 63:1117–1129.
- Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC, Kallen RG, Mandel G, Meisler MH, Netter YB, Noda M, Tamkun MM, Waxman SG, Wood JN, Catterall WA. 2000. Nomenclature of voltage-gated sodium channels. *Neuron* 28:368.
- Grafe P, Quasthoff S, Strupp M, Lehmann-Horn F. 1990. Enhancement of  $K^+$  conductance improves in vitro the contraction force of skeletal muscle in hypokalemic periodic paralysis. *Muscle Nerve* 13:451–457.
- Greenberg DA, Delgado-Escueta AV, Widelitz H, Sparkes RS, Treiman L, Maldonado HM, Park MS, Terasaki PI. 1988. Juvenile myoclonic epilepsy (JME) may be linked to the BF and HLA loci on human chromosome 6. *Am J Med Genet* 31:185–192.
- Hallmann K, Durner M, Sander T, Steinlein OK. 2000. Mutation analysis of the inwardly rectifying  $K(+)$  channels *KCNJ6* (GIRK2) and *KCNJ3* (GIRK1) in juvenile myoclonic epilepsy. *Am J Med Genet* 96:8–11.
- Haug K, Hallmann K, Horvath S, Sander T, Kubisch C, Rau B, Dullinger J, Beyenburg S, Elger CE, Propping P, Heils A. 2000a. No evidence for association between the *KCNQ3* gene and susceptibility to idiopathic generalized epilepsy. *Epilepsy Res* 42:57–62.
- Haug K, Sander T, Hallmann K, Rau B, Dullinger JS, Elger CE, Propping P, Heils A. 2000b. The voltage-gated sodium channel  $\beta$ 2-subunit gene and idiopathic generalized epilepsy. *Neuroreport* 11:2687–2689.
- Hille B. 1992. Ionic channels of excitable membranes. Sunderland: Sinauer.
- Hirose S, Iwata H, Akiyoshi H, Kobayashi K, Ito M, Wada K, Kaneko S, Mitsudome A. 1999. A novel mutation of *CHRNA4* responsible for autosomal dominant nocturnal frontal lobe epilepsy. *Neurology* 53:1749–1753.
- Hirose S, Zenri F, Akiyoshi H, Fukuma G, Iwata H, Inoue T, Yonetani M, Tsutsumi M, Muranaka H, Kurokawa T, Hanai T, Wada K, Kaneko S, Mitsudome A. 2000. A novel mutation of *KCNQ3* (c.925T→C) in a Japanese family with benign familial neonatal convulsions. *Ann Neurol* 47:822–826.
- Jentsch TJ. 2000. Neuronal *KCNQ* potassium channels: physiology and role in disease. *Nat Neurosci Rev* 1:21–30.
- Kandel ER, Siegelbaum SA. 2000. Synaptic integration. In: Kandel ER, Schwartz JH, Jessel MT, editors. Principles of neural science. New York: McGraw Hill. p 207–228.
- Kearney JA, Plummer NW, Smith MR, Kapur J, Cummins TR, Waxman SG, Goldin AL, Meisler MH. 2001. A gain-of-function mutation in the sodium channel gene *Scn2a* results in seizures and behavioral abnormalities. *Neuroscience* 102:307–317.
- Kubisch C, Schroeder BC, Friedrich T, Lütjohann B, El-Amraoui A, Martin S, Petit C, Jentsch TJ. 1999. *KCNQ4*, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. *Cell* 96:437–446.
- Kuryatov A, Gerzanich V, Nelson M, Olale F, Lindstrom J. 1997. Mutation causing autosomal dominant nocturnal frontal lobe epilepsy alters  $Ca^{2+}$  permeability, conductance, and gating of human  $\alpha$ 4 $\beta$ 2 nicotinic acetylcholine receptors. *J Neurosci* 17:9035–9047.
- Labarca C, Schwarz J, Deshpande P, Schwarz S, Nowak MW, Fonck C, Nashmi R, Kofuji P, Dang H, Shi W, Fidan M, Khakh BS, Chen Z, Bowers BJ, Boulter J, Wehner JM, Lester HA. 2001. Point mutant mice with hypersensitive  $\alpha$ 4 nicotinic receptors show dopaminergic deficits and increased anxiety. *Proc Natl Acad Sci USA* 98:2786–2791.
- Lawson K. 2000. Potassium channel openers as potential therapeutic weapons in ion channel disease. *Kidney Int* 57:838–845.
- Lehmann-Horn F, Jurkat-Rott K. 1999. Voltage-gated ion channels and hereditary disease. *Physiol Rev* 79:1317–1372.
- Lehmann-Horn F, Jurkat-Rott K. 2000. Channelopathies: common mechanisms in aura, arrhythmia and alkalosis. Amsterdam: Elsevier.
- Leppert M, Anderson VE, Quattlebaum T, Stauffer D, O'Connell P, Nakamura Y, Lalouel JM, White R. 1989. Benign familial neonatal convulsions linked to genetic markers on chromosome 20. *Nature* 337:647–648.
- Lerche H, Mitrovic N, Dubowitz V, Lehmann-Horn F. 1996. Paramyotonia congenita: the R1448P sodium channel mutation in adult human skeletal muscle. *Ann Neurol* 39:599–608.
- Lerche H, Biervert C, Alekov AK, Schleithoff L, Lindner M, Klingler W, Bretschneider F, Mitrovic N, Jurkat-Rott K, Bode H, Lehmann-Horn F, Steinlein OK. 1999. A reduced  $K^+$  current due to a novel mutation in *KCNQ2* causes neonatal convulsions. *Ann Neurol* 46:305–312.
- Lerche C, Scherer CR, Seeböhm G, Derst C, Wei AD, Busch AE, Steinmeyer K. 2000a. Molecular cloning and functional expression of *KCNQ5*, a potassium channel subunit that may contribute to neuronal M-current diversity. *J Biol Chem* 275:22395–22400.
- Lerche C, Seeböhm G, Schiebe M, Busch AE, Lerche H. 2000b. Evidence for assembly of *KCNQ2* and *KCNQ3*  $K^+$  channels via the C-terminus. *Soc Neurosci Abstr* 26:1909.
- Lerche H, Weber YG, Baier H, Jurkat-Rott K, Kraus de Camargo O, Ludolph AC, Bode H, Lehmann-Horn F. 2001. Generalized epilepsy with febrile seizures plus: further heterogeneity in a large family. *Neurology* (in press).
- Lewis TB, Leach RJ, Ward K, O'Connell P, Ryan SG. 1993. Genetic heterogeneity in benign familial neonatal convulsions: identification of a new locus on chromosome 8q. *Am J Hum Genet* 53:670–675.
- Li Z, Matsuoka S, Hryshko LV, Nicoll DA, Bersohn MM, Burke EP, Lifton RP, Philipson KD. 1994. Cloning of the *NCX2* isoform of the plasma membrane  $Na^+/Ca^{2+}$  exchanger. *J Biol Chem* 269:17434–17439.
- Litt M, Kramer P, Browne D, Gancher S, Brunt ERP, Root D, Phromchotikul T, Dubay CJ, Nutt J. 1994. A gene for episodic ataxia/myokymia maps to chromosome 12p13. *Am J Hum Genet* 55:702–709.
- Lopes-Cendes I, Scheffer IE, Berkovic SF, Rousseau M, Andermann E, Rouleau GA. 2000. A new locus for generalized epilepsy with febrile seizures plus maps to chromosome 2. *Am J Hum Genet* 66:698–701.
- Main MJ, Cryan JE, Dupere JRB, Cox B, Clare JJ, Burbidge SA. 2000a. Modulation of *KCNQ2/3* potassium channels by the novel anticonvulsant retigabine. *Mol Pharm* 58:253–262.
- Main MJ, Tatulian L, Cryan JE, Selyanko A, Brown D, Clare JJ, Hayes A, Trezise DJ, Burbidge SA. 2000b. Modulation of *KCNQ2* potassium channels by retigabine. *Soc Neurosci Abs* 26:1908.
- Maljevic S, Lerche C, Seeböhm G, Wuttke T, Alekov A, Busch AE, Lerche H. 2001. Evidence for assembly of *KCNQ2* and *KCNQ3*  $K^+$  channels via the C-terminus. *Pflügers Arch Eur J Physiol* 441:R143.
- Mehta AK, Ticku MK. 1999. An update on GABA-A receptors. *Brain Res Rev* 29:196–217.
- Miraglia del Giudice E, Coppola G, Scuccimarra G, Cirillo G, Bellini G, Pascotto A. 2000. Benign familial neonatal convulsions (BFNC) resulting from mutation of the *KCNQ2* voltage sensor. *Eur J Med Genet* 8:994–997.
- Mitrovic N, Lerche H. 2000. Sodium and calcium channelopathies of sarcolemma: periodic paralyses, paramyotonia congenita and potassium-aggravated myotonia. In: Lehmann-Horn F, Jurkat-Rott K, editors.

- Channelopathies—common mechanisms in aura, arrhythmia and alkalosis. Amsterdam: Elsevier-Science. p 3–32.
- Moulard B, Guipponi M, Chaigne D, Mouthon D, Buresi C, Malafosse A. 1999. Identification of a new locus for generalized epilepsy with febrile seizures plus (GEFS+) on chromosome 2q24–q33. *Am J Hum Genet* 65:1396–1400.
- Neubauer BA, Fiedler B, Himmelein B, Kämpfer F, Läßker U, Schwabe G, Spanier I, Tams D, Bretscher O, Moldenhauer K, Kurlemann G, Weise S, Tedroff K, Eeg-Olofsson O, Wadelius C, Stephani U. 1998. Centromeric spikes in families with rolandic epilepsy. Linkage to chromosome 15q14. *Neurology* 51:1608–1612.
- Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SMG, Lamerdin JE, Mohnweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJB, Hofker MH, Ferrari MD, Frants RR. 1996. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the  $Ca^{2+}$  channel gene CACNL1A4. *Cell* 87:543–552.
- Pfeiffer A, Thompson J, Charlier C, Otterud B, Varvil T, Pappas C, Barnitz C, Gruenthal K, Kuhn R, Leppert M. 1999. A locus for febrile seizures (FEB3) maps to chromosome 2q23–24. *Ann Neurol* 46:671–678.
- Phillips HA, Scheffer IE, Berkovic SF, Hollway GE, Sutherland GR, Mulley JC. 1995. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2. *Nat Genet* 10:117–118.
- Phillips HA, Marini C, Scheffer IE, Sutherland GR, Mulley JC, Berkovic SF. 2000. A de novo mutation in sporadic nocturnal frontal lobe epilepsy. *Ann Neurol* 48:264–267.
- Phillips HA, Favre I, Kirkpatrick M, Zuberi SM, Goudie D, Heron SE, Scheffer IE, Sutherland GR, Berkovic SF, Bertrand D, Mulley JC. 2001. *CHRNA2* is the second acetylcholine receptor subunit associated with autosomal dominant nocturnal frontal lobe epilepsy. *Am J Hum Genet* 68:225–231.
- Picard F, Bertrand S, Steinlein OK, Bertrand D. 1999. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. *Epilepsia* 40:1198–1209.
- Picard F, Baulac S, Kahane P, Hirsch E, Sebastianelli R, Thomas P, Vigeveno F, Genton P, Guerrini R, Gericke CA, An I, Rudolf G, Herman A, Brice A, Marescaux C, LeGuern E. 2000. Dominant partial epilepsies. A clinical, electrophysiological and genetic study of 19 European families. *Brain* 123:1247–1262.
- Plouin P. 1994. Benign idiopathic neonatal convulsions (familial and non-familial): open questions about these syndromes. In: Wolf P, editor. *Epileptic seizures and syndromes*. London: John Libbey & Co. p 193–201.
- Ptacek LJ. 1999. Ion channel diseases: episodic disorders of the nervous system. *Semin Neurol* 19:363–369.
- Quasthoff S, Spuler A, Spittelmeister W, Lehmann-Horn F, Grafé P. 1990.  $K^{+}$  channel openers suppress myotonic activity of human skeletal muscle in vitro. *Eur J Pharmacol* 186:125–128.
- Ronen GM, Rosales TO, Connolly M, Anderson VE, Leppert M. 1993. Seizure characteristics in chromosome 20 benign familial neonatal convulsions. *Neurology* 43:1355–1360.
- Ross SA, Wong JY, Clifford JJ, Kinsella A, Massalas JS, Horne MK, Scheffer IE, Kola I, Waddington JL, Berkovic SF, Drago J. 2000. Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. *J Neurosci* 20:6431–6441.
- Rundtfeld C, Netzer R. 2000. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human *KCNQ2/3* subunits. *Neurosci Lett* 282:73–76.
- Sander T, Bockenkamp B, Hildmann T, Blasczyk R, Kretz R, Wienker TF, Volz A, Schmitz B, Beck-Mannagetta G, Rieß O, Epplen JT, Janz D, Ziegler A. 1997. Refined mapping of the epilepsy susceptibility locus EJM1 on chromosome 6. *Neurology* 49:842–847.
- Sander T, Peters C, Janz D, Bianchi A, Bauer G, Wienker TF, Hildmann T, Epplen JT, Riess O. 1998. The gene encoding the alpha1A-voltage-dependent calcium channel (*CACNL1A4*) is not a candidate for causing common subtypes of idiopathic generalized epilepsy. *Epilepsy Res* 29:115–122.
- Sander T, Scholz L, Janz D, Epplen JT, Riess O. 1999. Length variation of a polyglutamine array in the gene encoding a small-conductance, calcium-activated potassium channel (*hKCa3*) and susceptibility to idiopathic generalized epilepsy. *Epilepsy Res* 33:227–233.
- Sander T, Schulz H, Saar K, Gennaro E, Riggio MC, Bianchi A, Zara F, Luna D, Bulteau C, Kaminska A, Ville D, Cuieta C, Picard F, Prud'homme JF, Bate L, Sundquist A, Gardiner RM, Janssen GA, Haan CJ, Kasteleijn-Nolst-Trenite DG, Bader A, Lindhout D, Riess O, Wienker TF, Janz D, Reis A. 2000. Genome search for susceptibility loci of common idiopathic generalised epilepsies. *Hum Mol Genet* 9:1465–1472.
- Scheffer IE, Berkovic SF. 1997. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. *Brain* 120:479–490.
- Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. 1994. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. *Lancet* 343:515–517.
- Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. 1995. Autosomal dominant nocturnal frontal lobe epilepsy: a distinct clinical disorder. *Brain* 118:61–73.
- Schmitt N, Schwarz M, Peretz A, Abitbol I, Attali B, Pongs O. 2000. A recessive C-terminal Jervell and Lange-Nielsen mutation of the *KCNQ1* channel impairs subunit assembly. *EMBO J* 19:332–340.
- Schroeder BC, Kubisch C, Stein V, Jentsch TJ. 1998. Moderate loss of function of cyclic-AMP-modulated *KCNQ2/KCNQ3*  $K^{+}$  channels causes epilepsy. *Nature* 396:687–690.
- Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ. 2000. *KCNQ5*, a novel potassium channel broadly expressed in brain, mediates M-type currents. *J Biol Chem* 275:24089–24095.
- Schultz D, Litt M, Smith L, Thayer M, McCormick K. 1996. Localization of two potassium channel beta subunit genes, *KCNA1B* and *KCNA2B*. *Genomics* 31:389–391.
- Schwake M, Pusch M, Kharkovets T, Jentsch TJ. 2000. Surface expression and single channel properties of *KCNQ2/KCNQ3*, M-type  $K^{+}$  channels involved in epilepsy. *J Biol Chem* 275:13343–13348.
- Serratos JM, Delgado-Escueta AV, Medina MT, Zhang Q, Iranmanesh R, Sparkes RS. 1996. Clinical and genetic analysis of a large pedigree with juvenile myoclonic epilepsy. *Ann Neurol* 39:187–195.
- Shapiro MS, Roche JP, Kaftan EJ, Cruzblanca H, Mackie K, Hille B. 2000. Reconstitution of muscarinic modulation of the *KCNQ2/KCNQ3*  $K^{+}$  channels that underlie the neuronal M current. *J Neurosci* 20:1710–1721.
- Siegelbaum SA, Koester J. 2000. Ion channels. In: Kandel ER, Schwartz JH, Jessell MT, editors. *Principles of neural science*. New York: McGraw Hill. p 105–124.
- Sieghart W, Fuchs K, Tretter V, Ebert V, Jechlinger M, Hoger H, Adamiker D. 1999. Structure and subunit composition of GABA(A) receptors. *Neurochem Int* 34:379–385.
- Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, McHarg ML, Gagnon D, Rosales TO, Pfeiffer A, Anderson E, Leppert M. 1998. A novel potassium channel gene, *KCNQ2*, is mutated in an inherited epilepsy of newborns. *Nat Genet* 18:25–29.
- Singh R, Scheffer IE, Crossland K, Berkovic SF. 1999. Generalized epilepsy with febrile seizures plus: a common childhood-onset genetic epilepsy syndrome. *Ann Neurol* 45:75–81.
- Smart SL, Lopantsev V, Zhang CL, Robbins CA, Wang H, Chiu SY, Schwartzkroin PA, Messing A, Tempel BL. 1998. Deletion of the *Kv1.1* potassium channel causes epilepsy in mice. *Neuron* 20:809–819.
- Smith JS, Iannotti CA, Dargis P, Christian EP, Aiyar J. 2001. Differential expression of *KCNQ2* splice variants: implications to M current function during neuronal development. *J Neurosci* 21:1096–1103.
- Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF. 1995. A missense mutation in the neuronal nicotinic acetylcholine receptor  $\alpha 4$  subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet* 11:201–203.
- Steinlein OK, Magnusson A, Stoodt J, Bertrand S, Weiland S, Berkovic SF, Nakken KO, Propping P, Bertrand D. 1997a. An insertion mutation of the *CHRNA4* gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. *Hum Mol Genet* 6:943–947.
- Steinlein OK, Sander T, Stoodt J, Kretz R, Janz D, Propping P. 1997b. Possible association of a silent polymorphism in the neuronal nicotinic acetylcholine receptor subunit alpha4 with common idiopathic generalized epilepsies. *Am J Med Genet* 74:445–449.

- Steinlein OK, Stoodt J, Biervert C, Janz D, Sander T. 1999. The voltage gated potassium channel *KCNQ2* and idiopathic generalized epilepsy. *Neuroreport* 10:1163–1166.
- Sugimoto Y, Morita R, Amano K, Fong CY, Shah PU, Castroviejo IP, Khan S, Delgado-Escueta AV, Yamakawa K. 2000. Childhood absence epilepsy in 8q24: refinement of candidate region and construction of physical map. *Genomics* 68:264–272.
- Swann JW, Smith KL, Brady RJ, Pierson MG. 1993. Neurophysiological studies of alterations in seizure susceptibility during brain development. In: Schwartzkroin PA, editor. *Epilepsy: models, mechanisms and concepts*. Cambridge: Cambridge University Press. p 209–243.
- Tinel N, Lauritzen I, Chouabe C, Lazdunski M, Borsotto M. 1998. The *KCNQ2* potassium channel: splice variants, functional and developmental expression. Brain localization and comparison with *KCNQ3*. *FEBS Lett* 438:171–176.
- Van Dyke DH, Griggs RC, Murphy MJ, Goldstein MN. 1975. Hereditary myokymia and periodic ataxia. *J Neurol* 25:109–118.
- Wallace RH, Wang DW, Singh R, Scheffer IE, George AL Jr, Phillips HA, Saar K, Reis A, Johnson EW, Sutherland GR, Berkovic SF, Mulley JC. 1998. Febrile seizures and generalized epilepsy associated with a mutation in the  $\text{Na}^+$  channel  $\beta_1$  subunit gene *SCN1B*. *Nat Genet* 19:366–370.
- Wallace RH, Scheffer IE, Barnett S, Richards M, Dibbens L, Desai RR, Lerman-Sagie T, Lev D, Mazarib A, Brand N, Ben-Zeev B, Goikman I, Singh R, Kremmidiotis G, Gardner A, Sutherland GR, George AL Jr, Mulley JC, Berkovic SF. 2001a. Neuronal sodium-channel  $\alpha 1$ -subunit mutations in generalized epilepsy with febrile seizures plus. *Am J Hum Genet* 68:859–865.
- Wallace RH, Marini C, Petrou S, Harkin LA, Bowser DN, Panchal RG, Williams DA, Sutherland GR, Mulley JC, Scheffer IE, Berkovic SF. 2001b. Mutant GABA-A receptor  $\gamma 2$ -subunit in childhood absence epilepsy and febrile seizures. *Nat Genet* 28:49–52.
- Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. 1996. Positional cloning of a novel potassium channel gene: *KVLQT1* mutations cause cardiac arrhythmias. *Nat Genet* 12:17–23.
- Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, McKinnon D. 1998. *KCNQ2* and *KCNQ3* potassium channel subunits: molecular correlates of the M-channel. *Science* 282:1890–1893.
- Weiland S, Witzemann V, Villarroel A, Propping P, Steinlein O. 1996. An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. *FEBS Lett* 398:91–96.
- Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. 2000. Retigabine, a novel anti-convulsant, enhances activation of *KCNQ2/3* potassium channels. *Mol Pharmacol* 58:591–600.
- Wollnik B, Schroeder BC, Kubisch C, Esperer HD, Wieacker P, Jentsch TJ. 1997. Pathophysiological mechanisms of dominant and recessive *KVLQT1*  $\text{K}^+$  channel mutations found in inherited cardiac arrhythmias. *Hum Mol Gen* 6:1943–1949.
- Yang W-P, Levesque PC, Little WA, Conder ML, Ramakrishnan P, Neubauer MG, Blannar MA. 1998. Functional expression of two *KvLQT1*-related potassium channels responsible for an inherited idiopathic epilepsy. *J Biol Chem* 273:19419–19423.
- Zara F, Bianchi A, Avanzini G, Di Donato S, Castellotti B, Patel PI, Pandolfo M. 1995. Mapping of genes predisposing to idiopathic generalized epilepsy. *Hum Mol Genet* 4:1201–1207.
- Zerr P, Adelman JP, Maylie J. 1998. Characterization of three episodic ataxia mutations in the human *Kv1.1* potassium channel. *FEBS Lett* 431:461–464.
- Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC. 1997. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the  $\alpha_{1A}$ -voltage-dependent calcium channel. *Nat Genet* 15:62–69.
- Zuberi SM, Eunson LH, Spauschus A, De Silva R, Tolmie J, Wood NW, McWilliam RC, Stephenson JPB, Kullmann DM, Hanna MG. 1999. A novel mutation in the human voltage-gated potassium channel gene (*Kv1.1*) associates with episodic ataxia type 1 and sometimes with partial epilepsy. *Brain* 122:817–825.